Pancreatic cancer: ESMO Clinical Practice Guideline for diagnosis, treatment and follow-up
Cet article présente les recommandations de l'"European Society for Medical Oncology" concernant le diagnostic, le traitement et le suivi d'un cancer du pancréas
Details on incidence and epidemiology are covered in the Supplementary Material Section 1, available at Annals of Oncology online.
Risk factors: The opportunity to detect pancreatic cancer (PC) when potentially curable depends on early diagnosis and an ability to identify and screen high-risk populations before symptoms arise. Identification of a high-risk population is challenging and optimal screening tools remain unclear.1 Older age is the strongest risk factor; incidence peaks at 65-69 years in males and 75-79 years in females.2 A pooled analysis of 117 meta-analyses assigned a relative risk to a number of common risk factors (Supplementary Table S1, available at Annals of Oncology online).3
The vast majority (>80%) of PCs arise due to sporadically occurring somatic mutations. Only a small proportion are due to inherited deleterious germline mutations.1 Familial PC, defined as at least two first-degree relatives with PC, accounts for only 4%-10% of all cases. Variants in BRCA2 are the most common genetic abnormalities seen in familial PC. Other familial syndromes linked to PC are listed in Supplementary Table S2, available at Annals of Oncology online.
Annals of Oncology , article en libre accès, 2023